Gao Pengfei, Wang Jiayu, Su Zhen, Li Fayin, Zhang Xianlong
Department of Anesthesiology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huaian, China.
PPAR Res. 2021 Jan 22;2021:8894752. doi: 10.1155/2021/8894752. eCollection 2021.
Neuropathic pain is a public health problem. Although many pharmaceuticals are used to treat neuropathic pain, effective and safe drugs do not yet exist. In this study, we tested nociceptive responses in CCI rats, and ELISA assay was performed to examine the expression of proinflammatory cytokines. We found that amorfrutins significantly reduce the pain behaviors in CCI rats and suppress the expression of proinflammatory cytokines (TNF, IL-6, and IL-1) and chemokines (CCL2/CCR2) in the spinal cord. However, concurrent administration of a PPAR antagonist, GW9662, reversed the antihyperalgesic effect induced by amorfrutins. The results indicate that amorfrutins inhibit the inflammation and chemokine expression by activating PPAR, thus relieving neuropathic pain in CCI rats. Therefore, PPAR-CCL2/CCR2 pathway might represent a new treatment option for neuropathic pain.
神经性疼痛是一个公共卫生问题。尽管许多药物被用于治疗神经性疼痛，但尚未存在有效且安全的药物。在本研究中，我们检测了慢性压迫性损伤（CCI）大鼠的伤害性反应，并进行了酶联免疫吸附测定（ELISA）以检测促炎细胞因子的表达。我们发现阿莫弗鲁汀能显著减轻CCI大鼠的疼痛行为，并抑制脊髓中促炎细胞因子（肿瘤坏死因子、白细胞介素-6和白细胞介素-1）和趋化因子（CCL2/CCR2）的表达。然而，同时给予过氧化物酶体增殖物激活受体（PPAR）拮抗剂GW9662可逆转阿莫弗鲁汀诱导的抗痛觉过敏作用。结果表明，阿莫弗鲁汀通过激活PPAR抑制炎症和趋化因子表达，从而缓解CCI大鼠的神经性疼痛。因此，PPAR-CCL2/CCR2通路可能代表了一种治疗神经性疼痛的新选择。
